Ã series of new AZT conju~filtes with alkyl and oxyalkyl ether phospholipids was synthesized and evaluated for inhibitory activities against HIV-1 and HIV-2. The alkoxyethyl derivatives 6a-c proved 3-to 5-fold more active against HIV-1 and HIV-2 than the alkyl analogues 6d-f. A trend for higher activity with longer alkyl side-chains was observed. However, the analogues with the shortest chain possessed the most favourable therapeutic index.
Introduction 2',3'-Dideoxynucleosides (ddNs) have proved to be potent inhibitors of HIV, the aetiologic agent of AIDS (Mitsuya et al., 1985; Mitsuya and Broder, 1986; Balzarini et al., 1987 Balzarini et al., , 1988 . To interact with their target enzyme, the HIV-associated reverse transcriptase, the nucleosides must be phosphorylated intracellularly to their 5'-triphosphate derivatives (Furman et al., 1986; Starnes and Cheng, 1987; Hao et el., 1988; Johnson et al., 1988; Balzarini et al., 1989) .
Synthetic lipophilic phosphate derivatives of these nucleosides (ddNTPs) are of particular interest since they can penetrate the membranes of virally infected cells and may subsequently be subjected to in situ hydrolysis to the corresponding 5'-nucleotide, the first metabolite in the phosphorylation sequence, thus leading to the pharmaco-logically active 5 '-triphosphates (van Wijk et aI., 1991 '-triphosphates (van Wijk et aI., , 1994 Hostetler et al., 1992 Hostetler et al., , 1993 Mullah et al., 1992) .
With this rationale in mind, several research groups (Henin et al., 1991; Piantadosi et el., 1991; Meier et al., 1992; Puech et al., 1993; Sergheraert et al., 1993; Thomson et al., 1993; McGuigan et al., 1993 McGuigan et al., , 1994 have reported the synthesis of 5-0-phosphate derivatives of AZT, the most extensively used drug against HIV infections in humans. In particular, ether Ilpid-AZT conjugates have shown promising in vitro anti-HIV-1 activity with a 5-10 fold reduction in cytotoxicity as compared to AZT alone (Piantadosi et al., 1991) . It has also been reported that synthetic quaternary ammonium or phosphocholine containing lipids can be active against infectious HIV replication (Meyer et al., 1991; Pidgeon et el., 1993; Qiu and Pidgeon, 1994) .
We are especially interested in exploring the stereoelectronic requirements for optimal effectiveness of the lipid component of ether Iipid-AZT conjugates and their wider applicability in the antiviral field.
The present paper is a first effort in this direction in which we report on a series of alkyl and alkoxyethyl ether lipids bearing long aliphatic chains covalently linked to AZT through a phosphodiester bond.
Results

Chemistry
Alkoxyethanol 1a was obtained through monoprotection of ethylene glycol as the triphenyl methyl ether, subsequent alkylation with dodecyl bromide and removal of the trityl group. Analogues 1band 1c were obtained by the same synthetic route (Fig. 1 ). The synthesis of the target molecules 6a-f ( Fig. 1 ) was based on a widely used method for the formation of 3'-5'-internucleotide phosphotriester linkages (Chattopadhyaya and Reese, 1979) . Thus, alkoxyethanols 1a-c and commercially available long-chain alcohols 2a-c were reacted with excess 0chlorophenyl phosphorodi-(1,2,4-triazolide) (3) in pyridine/acetonitrile to afford the triethylammonium salts 4a-f after hydrolysis. These were in turn coupled with AZT in the presence of 1-mesitylenesulfonyl-3-nitro-1,2,4-triazole (MSNT) as condensing agent to yield phosphotrlesters 5a-f in good yields. Removal of the 0chlorophenyl group with tetra-n-butyl ammonium fluoride (i) NaH, DME, (iI) RBr, reflux; (c) (I) HCOOH/Et20, (ii) K 2C03 , MeOH, RT; (d) (i)py, 45 min, (iI) Et 3N/H20, 15 min; (e) MSNT, AZT, py, 12h; (f) (n-Bu)4WF, THF, 5h. (Welch et al., 1985) followed by treatment with Dowex W gave the desired conjugates 6a-f as viscous oils.
Antiviral activity
AZT and the test compounds 6a-f were evaluated for their anti-HIV-1 and anti-HIV-2 activities in human T-Iymphocyte (GEM) cells. In general, all compounds proved effective in inhibiting HIV replication in vitro, as shown in Table 1 . Furthermore, the test compounds exhibited similar antiviral activities against HIV-1 and HIV-2. As a rule, alkoxyethyl derivatives 6a-c proved 3-to 5-fold more inhibitory to HIV-1 and HIV-2 replication than the 6d-f derivatives. The number of methylene groups in the 5' side-chain of the test compounds did not seem to affect their antiviral activities greatly, although there may be a trend for higher activity with longer alkyl chains (compounds 6c and 6f). It is also interesting to note that conju-gate 6e, which contains 13 methylene groups in the 5' side-chain, showed an increased EG so in comparison with compounds 6d and 6f, which contain 11 and 15 methylene groups, respectively. Analogous behaviour was observed in the alkoxyethyl series (6a-c), although the differences were less marked.
The toxicity of the compounds for the GEM/O cells seems to be higher with the alkoxyethyl series (6a-c) than with the alkyl series (6d-f), and also appears to be higher the longer the alkyl chain at the 5'-position. However, the selectivity index of the conjugates 6a-c was better than that of compounds 6d-f, and overall was -10fold inferior to that of AZT in GEM cells.
Stability of compounds 6a and 6d
No detectable decomposition of conjugates 6a and 6d was observed in RPMI-1640 even after 13 days of incu- bation at 37 "C, In contrast, partial hydrolysis of compounds 6a and 6d, with the release of free AZT,' was observed in RPM1-1640 containing 10% FCS after 48 h incubation (AZT 12.5 and 5.9%, respectively, of the starting material). Complete hydrolysis did not take place, with conjugate 6a yielding 43% AZT and conjugate 6d 26% AZTeven after 13 days of incubation in RPMI-1640 containing 10% FCS. AZT-MP was not detected during the experiment. Thus, the alkoxyethyl derivative 6a seems to be hydrolysed to a greater extent than the alkyl derivative 6d. In addition, when the chemical hydrolysis of compounds 6a and 6d was studied in buffered aqueous solution adjusted at pH 2, 5, 7.4 and 10.6 at 37 "C, no detectable decomposition was observed even after 13 days.
Discussion
Conjugates 6a-d were shown to possess in vitro antiviral activities against HIV-1 and HIV-2. The alkoxyethyl derivatives 6a-c not only proved more inhibitory to HIV-1 and HIV-2 replication than the alkyl derivatives 6d-f, but also had better selectivity indices.
Since the conjugates 6a-f were intended to deliver free nucleotide into the intact cells, it was of interest to test their anti-HIV-2 activities against thymidine-kinase-deficient CEMffK-cells. When evaluated in this cell line, which is markedly deficient in cytosol thymidine kinase, the test compounds were found not to be very active (Table 1) . These data may imply that the conjugates 6a-f were not able to deliver the 5'-monophosphate derivative of AZT intracellularly because they release free AZT into the medium (possibly through the AZT-MP intermediate) before the AZT prodrug is taken up by the cells. In order to test this hypothesis, the hydrolytic behaviour of the phosphodiester derivatives 6a and 6d was examined under several different sets of conditions. Our results indicate that the conjugates are partially hydrolysed only in serum-containing medium, probably through phosphodiesterase and phosphatase activation by FCS. We therefore believe that the test compounds are not converted to their corresponding 5'-monophosphate derivatives intracellularly due to esterase and phosphatase activity present in the cell membrane and/or in the cytosol.
Since the prodrugs 6a and 6d release AZT upon hydrolysis, the anti-HIV-1 and anti-HIV-2 activities in CEM cells of the remaining portion of the conjugates, dodecyloxyethyl phosphate 7 and dodecyl phosphate 8, respectively, were studied ( Fig. 2 ). Both compounds were antivlrally inactive at subtoxic concentrations (>20 J..lg rnl" for compound 7 and >4 J..lg mr' for compound 8).
In conclusion, alkyl and alkoxyethyl ether lipids bearing long aliphatic chains covalently linked to AZT through a phosphodiester bond (6a-f) exhibit anti-HIV-1 and anti-HIV-2 activity in CEM cells, but they probably do not act by intracellular delivery of AZT-MP. We are in the process of elucidating the molecular mechanism of action of these AZT conjugates. 
Materials and Experimental procedures
Compounds
All reactions were carried out under scrupulously dry conditions. All NMR spectra were recorded in CDCI 3. 3lp NMR spectra were recorded on a Bruker AC 300 (121.44 MHz) instrument and are reported in units of Ii relative to 85% phosphoric acid as external standard; positive shifts are downfield. l3C NMR spectra were recorded on a Bruker AC 300 spectrometer operating at 75.43 MHz. Shifts are expressed in units of 0 relative to CDCI 3 at 7HlO ppm. Both phosphorus-31 and carbon-13 NMR spectra were proton noise decoupled, and all signals were singlets unless otherwise stated. 'H NMR spectra were recorded on a Bruker AC 300 spectrometer operating at 300 MHz and are reported in units of 0 relative to internal CHCI 3 at 7.24 ppm. Silica gel plates (Merck F254) were used for thin layer chromatography. Chromatographic purification was performed using silica gel (200-400 mesh). HPLC data were recorded using a Waters quaternary system with an ODS10 column and water/acetonitrile as eluent with a linear gradient from 80 to 0% water at 25 min, with a flow rate of 1 ml mln" and detection by UV at 254 nm.
Elemental analyses were carried out by the microanalytical section of the Institute of Organic and Pharmaceutical Chemistry of the National Hellenic Research Foundation.
Ethylene glycol mono(triphenyl methyl) ether
To a solution of ethylene glycol (11.4 ml, 0.2 mol) in a mixture of N,N-dimethylformamide/dichloromethane (20/170 ml) was added triethylamine (2.17 ml, 0.03 mol) and 4-dimethylaminopyridine (98 mg, 0.8 mmol). To the resulting solution was added, at O°C, triphenylchloromethane (5.58 g, 0.02 mol). The mixture was allowed to warm to room temperature and was stirred for 8 h. The reaction mixture was then diluted with dichloromethane, and washed with sat. aq. NH 4CI, H 20 and sat. aq. NaCI. The organic layer was dried (Na 2S04) and the solvent was evaporated in vacuo. Purification by flash column chromatography [Pet. Ether (40-60°C)/EtOAc 80/20] afforded the desired monoprotected ethylene glycol (4.26 g 70%): NMR 07.44-7.18 (m, 15H, ArH), 3.76-3.71 (m, 2H, CH 2 0 H), 3.25 (t, J=4.8Hz, 2H, CH 2CH20H), 1.93 (t, J=6.3Hz, 1H, OH).
General procedure for the preparation of 1-alkoxy-2-0-(triphenyl methyl) ethane
To a suspension of sodium hydride (1.5mmol) in 5 ml dimethoxyethane at 0°C was added dropwise a solution of ethylene glycol mono(triphenyl methyl) ether (1 mmol) in dimethoxyethane (3.5 ml). The resulting mixture was stirred at o°C for 30 min and at 25°C for an additional 30 min. The mixture was subsequently cooled to O°C and the appropriate alkyl bromide (1.25 mmol) was added dropwise. The reaction mixture was then refluxed until completion, cooled to O°C and quenched by the addition of methanol (0.5 ml). The mixture was then diluted with diethyl ether (50 ml) and washed with H 20 and sat. aq. NaCI. The organic layer was dried (Na 2S04) and the solvent was evaporated in vacuo. Purification by flash column chromatography [Pet. Ether (40-60°C)/EtOAc 80/20] afforded the desired 1-alkoxy-2-0-(triphenyl methyl) ethane.
1-dodecyloxy-2-0-(triphenyl methyl) ethane. Yield (340mg, 72%); NMR 0 7.43 (d, J=7.8Hz, 6H, ArH), 7.27-7.17 (m, 9H, ArH), 3.57 (t, J=5.1 Hz, 2H, OCH 2CH 20CH2 ) , 3.44 (t, J =6.5 Hz, 2H, OCH 2CH20CH2 ) , 3.18 (t, J=5.1 Hz, 2H, OCH 2CH20CH2 ) , 1.58-1.53 (rn, 2H, OCH 2CH2CH2 ) , 1.21 [bs, 18H, (CH 2 )g), 0.84 (t, J = 6.0 Hz, 3H, CH 2CH 3)' 1-tetradecyloxy-2-0-(triphenyl methyl) ethane. Yield (360 mg, 72%); NMR 07.43 (d, J=7.8 Hz, 6H, ArH), 7.27-7.17 (rn, 9H, ArH), 3.57 (t, J =5.1 Hz, 2H, OCH 2CH20CH2 ) , 3.44 (t, J=6.5Hz, 2H, OCH 2CH20CH,j, 3.18 (t, J=5.1 Hz, 2H, OCH 2CH20CH2 ) , 1.58-1.53 (rn, 2H, OCH 2CH 2CH2 ) , 1.21 [bs, 22H, (CH 2 ) , , ] , 0.84 (t, J =6.0Hz, 3H, CH 2CH 3 ) .
1-hexadecyloxy-2-0-(triphenyl methyl) ethane. Yield (359 mg, 68%); NMR 07.43 (d, J=8.1 Hz, 6H, ArH), 7.27-7.17 (m, 9H, ArH), 3.56 (t, J=5.1 Hz, 2H, OCH 2CH 20CH2 ) , 3.44 (t, J=6.5Hz, 2H, OCH 2CH20CH 2 ) , 3.16 (t, J=5.1 Hz, 2H, OCH 2CH20CH 2 ), 1.57-1.52 (m, 2H, OCH 2CH 2CH 2 ), 1.21 [bs, 26H, (CH 2 )' 3], 0.83 (t, J = 6.3 Hz, 3H, CH 2CH 3)'
General procedure for the preparation of 1-alkoxyetnene-e-ots
A solution of 1-alkoxy-2-0-(triphenyl methyl) ethane (1 mmol) in a mixture of formic acid (90%) (1 ml) and diethyl ether (1 ml) was stirred at 25°C until the reaction was completed. Addition of ether was followed by extraction with sat. aq. NaHC0 3, H 20 and sat. aq. NaCI. The solvent was evaporated in vacuo and the resulting solid was dissolved in methanol (10 ml) and K 2C03 (3 mmol) was added. The reaction mixture was stirred until the formate esters were completely hydrolysed. The mixture was then filtered and the filtrate diluted with ether and washed with sat. aq. NH 4CI, H 20 and sat. aq. NaCI. The organic layer was dried (Na2S04) and the solvent evaporated. Purification by flash column chromatography [Pet. Ether (40-60°C)/ethyl acetate 80/20] afforded the desired t-alkoxy-ethane-z-ol. (Baumann et aI., 1967) . Yield (214mg, 93%); NMR 0 3.69 (t, J=4.5Hz, 2H, CH 20H), 3.49 (t, J=4.5Hz, 2H, CH 2CH20H), 3.43·(t, J=6.7Hz, 2H, OCH 2 ) , 2.0 (bs, 1H, OH), 1.57-1.53 (m, 2H, OCH 2CH2 ) , 1.22 [bs, 18H, (CH 2 le], 0.84 (t, J =6.7Hz, CH 2CH 3 ) . (Baumann et aI., 1967) . Yield (225mg, 87%); NMR 0 3.69 (t, J=4.5Hz, 2H, CH 20H), 3.49 (t, J=4.5Hz, 2H, CH 2CH20H), 3.43 (t, J=6.7Hz, 2H, OCH 2 ) , 2.0 (bs, 1H, OH), 1.57-1.53 (rn, 2H, OCH 2CH 2 ) , 1.22 [bs, 22H, (CH 2 ) ,, ] , 0.84 (t, J=6.7Hz, CH 2CH 3 ) . (Baumann et aI., 1967) . Yield (212mg, 74%); NMR 0 3.69 (t, J=4.5Hz, 2H, CH 20H), 3.49 (t, J=4.5Hz, 2H, CH 2CH20H), 3.43 (t, J=6.7Hz, 2H, OCH 2 ) , 2.0 (bs, 1H, OH), 1.57-1.53 (m, 2H, OCH 2CH2 ) , 1.22 [bs, 26H, (CH 2 ) ' 3 ] , 0.84 (t, J = 6.7 Hz, CH 2CH 3 ) .
1-dodecyloxy-ethane-2-ol (1a)
1-tetradecyloxy-ethane-2-ol (1b)
t-nexeaecytoxy-emene-z-ot (1c)
General procedure for the preparation of o-chlorophenyl 5'-(3'-azido-3'-deoxy-thymidinyl) alkyl phosphates and o-chlorophenyI5'-(3'-azido-3'-deoxy-thymidinyl) 2-alkoxyethyl phosphates
To a solution of o-chlorophenyl phosphorodichloridate (0.35 ml, 2 mmol) in acetonitrile (8 ml) at O°C were sequentially added 1,2,4-triazole (310 mg, 4.5 mmol) and triethylamine (0.6 ml) and the mixture was stirred at 25°C for 30 min.
The appropriate alcohol (1 mmol) in pyridine (8 ml) was then added, and after a further period of 45 min triethylamine (0.7 ml) and water (0.2 ml) were added and the mixture was stirred for 10 min. The reaction mixture was poured into sat. aq. NaHCO s and extracted with dichloromethane. The organic phase was dried~(Na2S04) and evaporated in vacuo. The resulting chlorophenyl phosphate triethylammonium salt was used without further purification.
The chlorophenyl phosphate triethylammonium salt obtained above was dissolved in pyridine (5 ml). t-rneeltylenesultonyl-anitro-1,2,4-triazole (MSNT 390 mg, 1.34 mmol) and AZT (300 mg, 1.12 mmol) were added and the mixture was stirred at 25°C for 12 h. Sat. aq. NaHCO s was then added and the mixture extracted with dichloromethane. The organic phase was extracted with sat. aq. CuS0 4 to remove pyridine, dried (Na 2S04) and concentrated in vacuo. The residue was purified by flash column chromatography using a gradient of dichloromethane : acetone 90: 10-85 : 15. 1, 149.9, 135.0, 130.8, 128.0, 126.4, 121.4, 111.6, 84.7 (d), 84.6 (d), 82.2, 71.6, 69.1, 68.4, 67.34 (d), 60.3, 37.5, 31.9, 29.6, 29.4, 29.3, 26.0, 22.7, 14.1, 12.4; 53.77; H, 6.77; N, 10.45. Fdtind: C, 53.45; H, 6.71; N, 10.33. j"f 1, 149.9, 135.0, 130.7, 128.0, 126.4, 121.4, 111.6, 84.7 (d) , 84.6 (d), 82.1, 71.6, 69.1 (d), 68.4 (d), 67.3 (d), 60.3, 37.5, 31.9, 29.6, 26.0, 22.7, 14.1, 12.3; 55.05; H, 7.07; N, 10.03. Found: C, 54.72; H, 7.05; N, 9.93. S'-Azido-S'-deoxythymidine 5'-(o-chlorophenyl 2-hexadecyloxyethyl phosphate) (4e). Yield 57%; 1H NMR 0 8.56 (bs, 1H, NH), 7.47-7.11 (m, 5H, ArH, H6), 6.22 (t, J=6.6Hz, 1H, Hi'), 4.48-4.28 [m, 5H, H3', H5', P(O)OCH 2CH2), 4.04 (m, 1H, H4'), 3.65-3.62 [m, 2H, P(O)OCH 2CH2], 3.44-3.48 (m, 2H, OCH 2), 2.43-2.20 (m, 2H, H2'), 1.85 (5, 3H, 5-Me), 1.64 (m, 2H, OCH 2CH2), 1.23 [bs, 26H, (CH 2),3], 0.83 (t, J=6.7Hz, 3H, CH 2CH 3 ) ; l3C NMR 0 163. 3, 150.1, 135.0, 132.0, 130.7, 128.0, 126.4, 121.4, 111.6, 84.7, 82.2, 71.6, 69.1 (d), 68.4 (d), 67.3, 60.3, 37.6, 31.9, 29.8, 29.6, 29.4, 29.3, 26.0, 22.6, 14.1, 12.4; 56.23; H, 7.36; N, 9.64. Found: C, 56.48; H, 7.36; N, 9.55 . 9, 150.4, 135.0, 130.6, 127.9, 126.2, 121.3, 111.5, 84.7 (d), 81.9 (d), 69.6, 67.1, 60.0, 37.3, 31.7, 30.1, 29.45, 29.4, 29.3, 29.2, 29.1, 28.9, 25.1, 22.5, 14.0, 12.3; 53.72, H, 6.6; N, 11.19. Found: C, 54.13; H, 6.74; N, 10.88. 3'-Azido-3'deoxythymidine 5'-(o-chlorophenyl tetradecyl phosphate) (4e). Yield 49%; lH NMR 0 9.1 (bs, 1H, NH), 7.1-7.5 (m, 5H, ArH, H6), 6.2 (t, J=6.5Hz, 1H, H1'), 4.45-4.0 [m, 6H, H5', H3', P(O)OCH 2, H4'], 2.43-2.2 (m, 2H, H2'), 1.85 (5, 3H, 5-Me), 1.7 [rn, 2H, P(O)OCH 2CH2], 1.25 [m, 22H, (CH 2 )11 1, 0.8 (t, J=6.7Hz, 3H, CH 2CH3 ) ; 13CNMR 0 163.6,150.2, 135. 0, 130.7, 128.0, 126.3, 121.3, 111.5, 84.7(d), 82.1(d) , 69.7, 67.2, Novel lipophilic phosphodiester AZT derivatives 47 60.1, 37.4, 31.8. 30.2, 30.1, 29.6, 29.5, 29.4, 29.3, 29.0, 25.2, 22.6, 14.1, 12.4; 55.08; H, 6.93; N, 10.71. Found: C, 54.57; H, 6.97, N, . Yield 44%; 'H NMR 0 8.71 (bs, 1H, NH), 5H, ArH, H6), 6.2 (t, J=6.5Hz, 1H, Hi'), 5H, H3', H5', P(O) OCH 2], 4.01 (m, 1H, H4'), 2.4-2.2 (m, 2H, H2'), 1.84* (5, 1H, 5-Me), 1.64 [m, 2H, P(O)OCH 2CH2], 1.21 [m, 26H, (CH 2) ,3], 0.83 (t, J=6.7 Hz, 3H, CH2CH3 ) ; 3lp NMR 0~8. 22, 56.34; H, 7.24; N, 10.27. Found: C, 56.24; H, 7.24; N, 10.49. General procedure for the preparation of the final phosphodiesters Tetra-n -butylammonium fluoride (3 mmol 1M in THF) was added to a solution of the protected conjugate (5a-f) (1 mmol) in 10 ml of a mixture of tetrahydrofuran-pyridine-water (8 : 1 : 1 vlv/v). The mixture was then stirred at 25°C for 5 h and then worked up by addition of sat. aq. NaHCO s and extraction with dichloromethane. The organic phase was evaporated and the residue was applied to a short column and eluted with dichloromethane: methanol (gradient 95: 5-50: 50). The appropriate fractions were concentrated and treated with DOWEX 50WX8 (W) in methanol to afford the final phosphodiesters.
S'Azido-S'-deoxythymidine 5'-(2-dodecycloxyethyl phosphate) (6a). Yield 71%; HPLC 11.35 min; 1H NMR 0 7.43 (5, 1H, H6), 6.17 (t, J = 6.4 Hz, 1H, H1'), 4. 38-4.11 [m, 5H, H3', H5', P(O) OCH 2CH2], 3.99-3.97 (m, 1H, H4'), 3.61-3.58 [m, 2H, P(O)OCH 2CH2], 3.44-3.38 (m, 2H, OCH 2), 2.39-2.32 (m, 2H, H2'), 1.87 (5, 3H, 5-Me). 1.51 (m, 2H, OCH 2CH2 ) , 1.21 [bs, 18H, (CH 2 )g], 0.83 (t, J=6.7Hz, 3H, CH 2CH 3 ) ; 13CNMR 0 164. 3, 150.3, 135.8, 111.3, 84.96, 82.3 (d), 71.6, 69.1 (d), 66.9 (d), 66.1, 60.1, 37.5, 31.8, 29.5, 29.44, 29.39, 29.25, 25.9, 22.6, 14.0, 12.2; 51.51; H, 7.57; N, 12.52. Found: C, 51.44; H, 7.43; N, . Yield 60%; HPLC 14.48 min; 'H NMR 07.42 (5, 1H, H6), 6.17 (t, J = 6.3 Hz, 1H, Hi'), 4. 38-4.13 [rn, 5H, H3', H5', P(O) OCH 2CH2], 3.99-3.97 (m, 1H, H4'), 3.62-3.59 [m, 2H, P(O)OCH 2CH2], 3.44-3.38 (m, 2H, OCH 2), 2.39-2.32 (m, 2H, H2'), 1.87 (5, 3H, 5-Me), 1.51 (m, 2H, OCH 2CH 2 ) , 1.21 [bs, 22H, (CH 2 )11 ], 0.84 (t, J=6.7Hz, 3H, CH 2CH3 ) ; 13CNMR 0 164. 2, 150.2, 135.8, 111.3, 85.1, 82.4 (d), 71.7, 69.3 (d), 66.9 (d), 66.1, 60.1, 37.5, 31.9, 29.8, 29.7, 29.5, 29.3, 29.25, 25.9, 22.7, 14.1, 12.8; 53.14; H, 7.89; N, 11.91. Found: C, 53.53; H, 7.92; N, 3, 150.3, 135.8, 111.2, 85.0, 82.4 (d), 71.6, 69.2 (d), 66.9, 66.1, 60.1, 37.5, 31.8, 29.6, 29.5, 29.3, 25.9, 22.6, 14.0, 12.2; 54.62; H, 8.19; N, 11.37. Found: C, 54.93; H, 8.52 150.2, 135.7, 111.3, 85.1, 82.4, 68.2, 65.9, 59.9, 37.5, 31.8, 30.2, 29.6, 29.3, 29.1, 25.4, 22.6, 14.1, 12.3; Anal. Calcd. for C22H38N507P: C, 51.25; H, 7.43; N, 13.58. Found: C, 51.63; H, 7.34; N, . Yield 68%; HPLC 13.39 min; 1 H NMR 87.43 (s, 1H, H6), 6.2 (t, J = 6.2 Hz, 1H, H1'), 4.38-4.01 [m, 6H, H5', H3', P(O)OCH 2, H4'], 2.41-2.33 (m, 2H, H2'), 13CNMR 8164.2, 150.2, 135.7, 111.3, 85.1, 82.3, 68.2, 65.8, 59.9, 37.5, 31.8, 30.1, 29.6, 29.3, 29.1, 25.4, 22.6, 14.0, 12.3; Anal. Cated. for C24H42Ns07P 0.5H 20: C, 52.16; H, 7.84; N, 12.67. Found: C, 52.53; H, 7.90; N, . Yield 60%; HPLC 15.89 min; 'H NMR 8 7.45 (s, 1H, H6), 6.2 (t, J=6.2Hz, 1H, H1'), 4.38-4.22 (m, 3H, H5', H3'), 4.08-4.01 [m, 3H, P(O)OCH 2, H4'], 2.4-2.33 (m, 2H, H2'), 1.9 (s, 3H, 5Me), 1.67 [m, 2H, P(O)OCH 2CH 2], 1.24 [m, 26H, (CH 2 ), 3], 0.88 (t, J=6.7 Hz, 3H, CH 2CH3 ) ; 31p NMR 8 -1.71; Anal. Caled. for C26H46Ns07P: C, 54.63; H, 8.11; N, 12.25. Found: C, 54.25; H, 7.94; N, 12.13. 
Stability of compounds 6a and 6d
Conjugates 6a and 6d (1 mM concentrations) were incubated in the presence of RPMI-1640 culture medium and RPMI-1640 culture medium containing 10% fetal calf serum. The solutions were monitored by HPLC, using an ODS10 column, an eluant of water/acetonitrile and a linear gradient from 100% water to 20% water at 30 min, with a flow rate of 2 ml min -1 and detection by UV at 265 nm. Reverse-phase thin layer chromatography (RP-18 TLC plates, and eluant system of water/acetonitrile 1: 1) was also used for monitoring the solutions. For identification of the possible hydrolysis products AZT-MP, dOdecyloxyethylmonophosphate and dodecyl monophosphate were synthesized and used as standards.
Antiretroviral evaluation
Human immunodeficiency virus type 1 [HIV-1 (HTLV-III B ) ] was obtained from persistently HIV-infected H9 cells as previously described (Popovic et al., 1984) . HN-2 (ROD) was provided by Dr L. Montagnier (Pasteur Institute, Paris, France). CEM/O cells were obtained from the American Tissue Culture Collection (Rockville, MD), and CEM TK-cells were a gift from Prof. S. Eriksson and Dr A. Karlsson (Karolinska Institute, Stockholm, Sweden). CEM cells were infected with HIV-1 as previously described (Balzarini et al., 1991) . Briefly, 5 x 105 CEM cells ml-1 were infected with HIV-1 or HIV-2 at 100 CCID 50 (50% cell culture infective dose) per ml of cell suspension. 100 J..l 1 of the infected cell suspension was then transferred to microtitre plate wells and mixed with 100 pl of the appropriate dilutions of the test compounds. After 4 days, giant cell formation was recorded microscopically in the HIV-infected CEM cell cultures. The 50% effective concentration (EC 50) and the 50% cytotoxic concentration (CC 50) were defined as the compound concentrations required to reduce by 50% the number of giant cells or viable cells in the virus-infected and mock-infected cell cultures, respectively.
